A series of rejections by Perrigo’s management and board has spurred Mylan to go directly to its shareholders. Under the terms of the offer, Perrigo shareholders will receive US$75 in cash and 2.3 Mylan shares for each Perrigo share, making the deal worth around US$187 per share and an estimated US$27 billion overall.

Under Irish takeover rules, Mylan needs to convince investors holding 50.1% of Perrigo’s stock to sell for it to gain control. Perrigo CEO Joseph Papa has urged its shareholders to reject Mylan, saying that it was an ‘inadequate offer’. However, analysts believe Mylan should have no trouble getting this level of support, based on the fact that around 49% of Perrigo’s stock is owned either by hedge funds – most of which bought their shares in the past six months in anticipation of a deal – or large Mylan shareholders, which recently voted in favour of the takeover.

Mylan first announced it wanted to buy Perrigo in April 2015, when it was being pursued by Teva Pharmaceutical Industries [1].

Related article
Perrigo expands global ambitions with Elan buy

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Teva finally makes bid for Mylan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 9]. Available from: www.gabionline.net/Pharma-News/Teva-finally-makes-bid-for-Mylan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.